Articles

Recent articles

  1. Study protocol

    The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma

    Sarah Brown, Samantha Hinsley, Mónica Ballesteros, Sue Bourne, Paul McGarry, Debbie Sherratt, Louise Flanagan, Walter Gregory, Jamie Cavenagh, Roger Owen, Cathy Williams, Martin Kaiser, Eric Low and Kwee Yong

    Published on: 17 May 2016

  2. Study protocol

    Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

    Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Regina Garcia, Maria Teresa Voso, Stephen R. Larsen, David Valcarcel, Lewis R. Silverman, Barry Skikne and Valeria Santini

    Published on: 3 May 2016

View all articles

Most accessed articles

View all articles

Aims and scope

BMC Hematology is an open access, peer-reviewed journal that considers articles on basic, experimental and clinical research related to hematology. The journal welcomes submissions on non-malignant and malignant hematological diseases, hemostasis and thrombosis, hematopoiesis, stem cells and transplantation.

Section Editor

  • Mary J Laughlin, Division of Hematology/Oncology, University of Virginia
  • Alejandro Lazo-Langner, University of Western Ontario

Executive Editor

  • Nawsheen Boodhun, BioMed Central

Tweets

Advertisement